STOCK TITAN

Design Therapeutics, Inc. Stock Price, News & Analysis

DSGN Nasdaq

Welcome to our dedicated page for Design Therapeutics news (Ticker: DSGN), a resource for investors and traders seeking the latest updates and insights on Design Therapeutics stock.

Design Therapeutics, Inc. (DSGN) is a clinical-stage biopharmaceutical company advancing novel therapies for genetic disorders through its proprietary GeneTAC™ platform. This page serves as the definitive source for official company announcements, research developments, and regulatory updates.

Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, and scientific milestones across DSGN's pipeline targeting Friedreich ataxia, Fuchs endothelial dystrophy, and other degenerative genetic conditions. Our curated news collection provides:

• Clinical development updates
• Regulatory filings and approvals
• Research collaboration announcements
• Financial reporting disclosures

Bookmark this page for direct access to verified information about DSGN's innovative approach to gene-targeted therapies. Check regularly for new developments in genomic medicine and therapeutic advancements.

Rhea-AI Summary

Design Therapeutics, a clinical-stage biotechnology company focused on serious genetic diseases, announced that CEO João Siffert and COO Sean Jeffries will participate in a fireside chat at the 2022 Wedbush PacGrow Virtual Healthcare Conference on August 10, 2022, at 10:20 a.m. ET. A live webcast will be accessible on the company's investor website, with an archive available for 30 days post-event.

Design's GeneTAC™ platform aims to develop therapies addressing genetic disorders like Friedreich ataxia and myotonic dystrophy type-1, targeting disease-causing genes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
conferences
-
Rhea-AI Summary

Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology firm focused on serious degenerative genetic diseases, announced that CEO João Siffert will present at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 8:30 a.m. ET in New York City. A live webcast will be available on their investor website, archived for 30 days post-presentation. The company is known for its GeneTAC™ technology aimed at targeting genes responsible for diseases like Friedreich ataxia and myotonic dystrophy type-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
-
Rhea-AI Summary

Design Therapeutics, Inc. (Nasdaq: DSGN) reported significant advancements in its clinical and research pipeline, emphasizing the initiation of Phase 1 trials for its lead GeneTAC™ molecule, DT-216, aimed at treating Friedreich Ataxia. The company highlighted a robust cash position of $371.2 million, supporting its multi-year operational strategy. R&D expenses were $8.8 million for Q1 2022, contributing to a net loss of $13.3 million. DT-216 has been granted Fast Track designation by the FDA, expediting its development process, while promising results for Fuchs endothelial corneal dystrophy were also presented.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
Rhea-AI Summary

Design Therapeutics (Nasdaq: DSGN) has completed dosing in the Phase 1 clinical trial of DT-216 for Friedreich ataxia (FA). This novel GeneTAC™ small molecule targets the genetic mutation causing FA, aiming to restore frataxin gene expression. The FDA has granted DT-216 Fast Track designation, facilitating its development due to the urgent need for effective FA treatments. The randomized, double-blind study will assess safety and tolerability, with topline data expected in the second half of 2022. The Fast Track status allows for expedited communication with the FDA during drug development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
-
Rhea-AI Summary

Design Therapeutics (Nasdaq: DSGN) reported its fourth quarter and full year 2021 results, highlighting a significant milestone with the FDA clearance of its IND for DT-216, a GeneTAC™ targeting Friedreich ataxia. Total cash and investments stand at $384.1 million, ensuring ample resources for upcoming trials and projects. Research and development expenses for Q4 were $7.3 million, with a net loss of $11.1 million. The company is poised to present promising preclinical data on GeneTAC™ for Fuchs endothelial corneal dystrophy at ARVO 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
-
Rhea-AI Summary

Design Therapeutics has announced promising preclinical data for its GeneTAC™ small molecules targeting Fuchs endothelial corneal dystrophy (FECD). The data showed a reduction of up to 99% in toxic nuclear foci and restoration of normal splicing in affected corneal endothelial cells. FECD affects over one million people in the U.S., primarily due to a mutation in the TCF4 gene. Currently, no disease-modifying therapies exist, with corneal transplantation as the only treatment. The findings will be presented at the ARVO 2022 Annual Meeting, indicating a significant advancement in potential treatments for genetic disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.41%
Tags
Rhea-AI Summary

Design Therapeutics, Inc. (Nasdaq: DSGN) announced the FDA's clearance of its Investigational New Drug Application for DT-216, aimed at treating Friedreich ataxia. The Phase 1 clinical trial will evaluate the safety and tolerability of DT-216, with enrollment expected to begin shortly. This milestone underscores the potential of Design's GeneTAC™ platform for developing therapies addressing genetic disorders. DT-216 targets the GAA repeat expansion mutation to restore frataxin expression, vital for combating FA symptoms. Topline data from the trial is anticipated in the second half of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
Rhea-AI Summary

Design Therapeutics, a biotechnology company focused on developing treatments for degenerative genetic disorders, announced that CEO João Siffert and COO Sean Jeffries will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 11:20 a.m. ET. The event will be available via live webcast on the company's investor site, with an archive accessible for 30 days post-event. Design Therapeutics utilizes its GeneTAC™ platform to treat conditions like Friedreich ataxia and myotonic dystrophy type-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
conferences
-
Rhea-AI Summary

Design Therapeutics, Inc. (Nasdaq: DSGN) has appointed Dr. Jae Kim as Chief Medical Officer. With extensive experience in clinical strategy and drug development, Dr. Kim will lead the company’s transition to clinical trials, starting with a Phase 1 trial for Friedreich ataxia in early 2022. Dr. Kim previously served at Avidity Biosciences and Alnylam Pharmaceuticals, contributing to significant therapeutic approvals. His appointment is expected to enhance Design's capabilities in addressing genetic disorders through its GeneTAC™ technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
management
Rhea-AI Summary

Design Therapeutics, Inc. (Nasdaq: DSGN) announced significant progress in its pipeline, including the GeneTACTM program for Friedreich Ataxia, expected to initiate clinical trials in the first half of 2022. The company reported a net loss of $11.3 million for Q3 2021, with R&D expenses at $8.5 million. Positive preclinical data was highlighted for the DM1 GeneTACTM program, showcasing its potential to treat myotonic dystrophy type-1. As of September 30, 2021, the company held $393.7 million in cash and equivalents, positioning it well for upcoming developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none

FAQ

What is the current stock price of Design Therapeutics (DSGN)?

The current stock price of Design Therapeutics (DSGN) is $3.77 as of July 3, 2025.

What is the market cap of Design Therapeutics (DSGN)?

The market cap of Design Therapeutics (DSGN) is approximately 216.9M.
Design Therapeutics, Inc.

Nasdaq:DSGN

DSGN Rankings

DSGN Stock Data

216.86M
34.33M
36.36%
59.34%
5.67%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD